PLENVU Drug Patent Profile

When do Plenvu patents expire, and what generic alternatives are available?

Plenvu is a drug marketed by Salix and is included in one NDA. There are eleven patents protecting this drug and one Paragraph IV challenge.

This drug has one hundred and sixty-five patent family members in thirty-seven countries.

The generic ingredient in PLENVU is ascorbic acid; polyethylene glycol 3350; potassium chloride; sodium ascorbate; sodium chloride; sodium sulfate. There are six drug master file entries for this compound. Four suppliers are listed for this compound. Additional details are available on the ascorbic acid; polyethylene glycol 3350; potassium chloride; sodium ascorbate; sodium chloride; sodium sulfate profile page.

DrugPatentWatch^® Generic Entry Outlook for Plenvu

There have been four patent litigation cases involving the patents protecting this drug, indicating strong interest in generic launch. Recent data indicate that 63% of patent challenges are decided in favor of the generic patent challenger and that 54% of successful patent challengers promptly launch generic drugs.

Indicators of Generic Entry

Summary for PLENVU

International Patents:	165
US Patents:	11
Applicants:	1
NDAs:	1
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for PLENVU

Paragraph IV (Patent) Challenges for PLENVU

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
PLENVU	For Oral Solution	ascorbic acid; polyethylene glycol 3350; potassium chloride; sodium ascorbate; sodium chloride; sodium sulfate	140 g, 5.2 g, 2.2.g, 48.11 g, 9 g and 7.54 g per pouch	209381	1	2018-12-06

US Patents and Regulatory Information for PLENVU

PLENVU is protected by eleven US patents.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Salix	PLENVU	ascorbic acid; polyethylene glycol 3350; potassium chloride; sodium ascorbate; sodium chloride; sodium sulfate	FOR SOLUTION;ORAL	209381-001	May 4, 2018		RX	Yes	Yes
Salix	PLENVU	ascorbic acid; polyethylene glycol 3350; potassium chloride; sodium ascorbate; sodium chloride; sodium sulfate	FOR SOLUTION;ORAL	209381-001	May 4, 2018		RX	Yes	Yes			Y
Salix	PLENVU	ascorbic acid; polyethylene glycol 3350; potassium chloride; sodium ascorbate; sodium chloride; sodium sulfate	FOR SOLUTION;ORAL	209381-001	May 4, 2018		RX	Yes	Yes			Y

International Patents for PLENVU

When does loss-of-exclusivity occur for PLENVU?

Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:

Argentina

Australia

Brazil

Canada

China

Croatia

Cyprus

Denmark

Eurasian Patent Organization

European Patent Office

Hong Kong

Hungary

India

Ireland

Israel

Japan

Lithuania

Malaysia

Mexico

Montenegro

Netherlands

New Zealand

Poland

Portugal

San Marino

Serbia

Singapore

Slovenia

South Africa

South Korea

Spain

Taiwan

Ukraine

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

See the table below for additional patents covering PLENVU around the world.

Country	Patent Number	Title	Estimated Expiration
Australia	2018204694	COMPOSITIONS COMPRISING PEG AND ASCORBATE
Japan	2015527385
South Korea	101896919

Supplementary Protection Certificates for PLENVU

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
3141251	C202130017	Spain		PRODUCT NAME: COMBINACION DE PRINCIPIOS ACTIVOS EN DOS DOSIS, EN LA QUE LA PRIMERA DOSIS CONSISTE EN LOS PRINCIPIOS ACTIVOS POLIETILENGLICOL, SULFATO DE SODIO, CLORURO DE SODIO Y CLORURO DE POTASIO, Y LA SEGUNDA DOSIS CONSISTE EN LOS PRINCIPIOS ACTIVOS POLIETILENGLICOL, ACIDO ASCORBICO, ASCORBATO DE SODIO, CLORURO DE SODIO Y CLORURO DE POTASIO.; NATIONAL AUTHORISATION NUMBER: 82959-SE/H/1801/001/DC; DATE OF AUTHORISATION: 20180525; NUMBER OF FIRST AUTHORISATION IN EUROPEAN ECONOMIC AREA (EEA): IS/1/17/083/01; DATE OF FIRST AUTHORISATION IN EEA: 20171016
3141251	301099	Netherlands		PRODUCT NAME: A MEDICINAL PRODUCT CONSISTING OF A COMBINATION OF A FIRST DOSE PHARMACEUTICAL COMPOSITION AND A SECOND DOSE PHARMACEUTICAL COMPOSITION, THE FIRST DOSE PHARMACEUTICAL COMPOSITION CONSISTING OF THE ACTIVE INGREDIENTS POLYETHYLENE GLYCOL, SODIUM SULPHATE, SODIUM CHLORIDE AND POTASSIUM CHLORIDE AND THE SECOND DOSE PHARMACEUTICAL COMPOSITION CONSISTING OF THE ACTIVE INGREDIENTS POLYETHYLENE GLYCOL, ASCORBIC ACID, SODIUM ASCORBATE, SODIUM CHLORIDE AND POTASSIUM CHLORIDE; NATIONAL REGISTRATION NO/DATE: RVG 120195 20171114; FIRST REGISTRATION: IS IS/1/17/083/01 20171016
3141251	SPC/GB20/075	United Kingdom		PRODUCT NAME: A MEDICINAL PRODUCT CONSISTING OF A COMBINATION OF A FIRST DOSE PHARMACEUTICAL COMPOSITION AND A SECOND DOSE PHARMACEUTICAL COMPOSITION, THE FIRST DOSE PHARMACEUTICAL COMPOSITION CONSISTING OF THE ACTIVE INGREDIENTS: POLYETHYLENE GLYCOL 3350, SODIUM SULPH; REGISTERED: IS IS/1/17/063/01 20171016; UK PL 20011/0040 20171016

PLENVU: Investment and Fundamentals Analysis

Last updated: February 19, 2026

PLENVU, a novel formulation of polyethylene glycol (PEG) for bowel preparation, presents a compelling investment opportunity driven by its differentiated efficacy, favorable safety profile, and expanding market penetration. This analysis examines the drug's fundamental strengths, competitive landscape, and intellectual property to inform strategic R&D and investment decisions.

What is PLENVU's Core Value Proposition?

PLENVU offers superior bowel cleansing compared to standard PEG formulations, demonstrated by higher cecal intubation rates and improved visualization during colonoscopies. Its unique formulation combines PEG with electrolytes and ascorbic acid, enhancing palatability and patient compliance, key factors in achieving effective bowel preparation. This leads to reduced procedure failure rates and potentially lower healthcare costs associated with repeat procedures or incomplete diagnostics.

How Does PLENVU Differentiate in the Market?

PLENVU's primary differentiation lies in its clinical performance and patient experience.

Clinical Efficacy Benchmarks

• Cecal Intubation Rates: Clinical trials show PLENVU achieving cecal intubation rates of 94.8% and 93.2% in separate arms, compared to historical benchmarks for standard PEG formulations often ranging from 85-90% [1].
• Adenoma Detection Rates (ADR): Studies indicate a potential for improved ADR with PLENVU, attributed to better mucosal visualization. While direct head-to-head comparisons against all competitors are ongoing, the improved bowel prep quality is a surrogate for better adenoma detection.
• Overall Quality of Preparation: PLENVU consistently scores higher on standardized bowel preparation scales, such as the Boston Bowel Preparation Scale (BBPS), indicating a more complete and uniform cleansing. Scores of 6.3 (left colon), 6.5 (transverse colon), and 6.4 (right colon) have been reported, signifying excellent preparation [1].

Patient Experience Advantages

• Palatability: The addition of ascorbic acid and reduced salt concentration contributes to a significantly improved taste profile compared to traditional PEG solutions, which are often described as unpalatable. Patient preference scores in studies favor PLENVU over standard PEG formulations [2].
• Tolerability: PLENVU's electrolyte balance aims to minimize fluid shifts and electrolyte disturbances, enhancing tolerability and reducing the incidence of nausea and vomiting, common complaints with older bowel prep agents.
• Dosage Regimen: The typical dosage regimen involves a split-dose administration (e.g., evening before and morning of the procedure), which is considered optimal for effective bowel cleansing and is consistent with leading-edge practice.

What is the Competitive Landscape for Bowel Preparation Agents?

The bowel preparation market is competitive, with established players and emerging alternatives. PLENVU competes across several categories:

Major Competitive Classes

• Polyethylene Glycol (PEG)-Based Solutions: This is PLENVU's primary competitive set. Competitors include generic PEG 3350 solutions, MiraLAX (prescription PEG 3350), and other branded PEG formulations. PLENVU distinguishes itself through its enhanced efficacy and palatability.
• Low-Volume PEG Solutions: These formulations, like SUPREP (magnesium citrate and sodium picosulfate) and SUTAB (magnesium sulfate, citric acid, potassium sulfate), offer reduced volume but can have different electrolyte profiles and potential side effects.
• Sodium Phosphate Solutions: Historically used, these have largely been supplanted due to risks of renal toxicity, particularly in patients with compromised kidney function or dehydration.
• Newer Formulations: Emerging products may focus on alternative mechanisms or novel delivery methods.

Market Share and Penetration

While specific, up-to-the-minute market share data for PLENVU is proprietary and dynamic, industry reports indicate a significant shift towards split-dose, low-volume, and more palatable preparations. PLENVU has gained traction in key markets, particularly in Europe and North America, through strategic partnerships and formulary approvals. Its adoption is driven by gastroenterologists seeking to optimize procedural outcomes and improve patient satisfaction.

What is the Intellectual Property (IP) Protection for PLENVU?

PLENVU's market exclusivity is underpinned by a robust patent portfolio and regulatory exclusivity.

Key Patents and Exclusivity Periods

• Composition of Matter Patents: Patents protecting the specific formulation of PLENVU, including its unique combination of active ingredients and excipients. These patents typically have a term extending 20 years from the filing date, subject to extensions like the Patent Term Extension (PTE) in the United States.
• Method of Use Patents: Patents covering specific methods of administering PLENVU for bowel preparation, potentially offering protection even if a generic competitor emerges with a similar composition.
• Manufacturing Process Patents: Patents related to the efficient and proprietary manufacturing of PLENVU.
• Regulatory Exclusivity: Upon FDA approval (or equivalent regulatory bodies), PLENVU benefits from various forms of market exclusivity, such as:
  • New Chemical Entity (NCE) Exclusivity: Typically 5 years in the US for novel drugs.
  • Orphan Drug Exclusivity: If applicable, can extend exclusivity.
  • Pediatric Exclusivity: An additional 6 months granted for studies conducted in children.
  • Data Exclusivity: Protection of clinical trial data from generic referencing, typically 5 years in the US and 10 years in Europe.

The expiration dates of key patents and the timing of generic entry are critical factors in investment modeling. Analysis of patent landscapes reveals that primary composition of matter patents for PLENVU's core formulation are generally protected for the coming years, with some patents extending into the late 2030s. The specific interplay of patent term extensions and potential litigation can influence the effective market exclusivity period.

What are the Market Drivers and Growth Opportunities?

Several factors are driving the demand for advanced bowel preparation agents like PLENVU.

Market Trends

• Increasing Colonoscopy Rates: Aging populations globally, coupled with heightened awareness and screening guidelines for colorectal cancer, are driving an increase in the volume of colonoscopies performed annually. This directly expands the market for effective bowel preparation agents.
• Focus on Procedural Quality: Payers and healthcare providers are increasingly emphasizing the quality of colonoscopy procedures, including adenoma detection rates. Superior bowel preparation is recognized as a critical factor in achieving these quality metrics.
• Patient-Centric Care: There is a growing demand for treatments that improve patient comfort, compliance, and overall experience. The palatability and tolerability advantages of PLENVU align with this trend.
• Shift to Split-Dosing: The medical community widely recognizes split-dose regimens as superior for bowel preparation. Drugs designed for and optimized with split-dosing, like PLENVU, benefit from this practice.

Growth Opportunities

• Geographic Expansion: Continued penetration into new international markets, particularly in Asia and Latin America, where screening rates and adoption of advanced formulations are growing.
• New Indications/Formulations: Potential for development of modified formulations or expanded indications for specific patient populations (e.g., patients with inflammatory bowel disease, renal impairment) requiring specialized bowel preparation.
• Combination Therapies: Exploring use in conjunction with other diagnostic or therapeutic agents delivered via colonoscopy.
• Value-Based Healthcare: Demonstrating cost-effectiveness through reduced repeat procedures, fewer complications, and improved diagnostic yield can lead to preferential formulary placement and reimbursement.

What are the Risks and Challenges?

Despite its strengths, PLENVU faces potential challenges.

Identified Risks

• Generic Competition: As patents approach expiration, generic manufacturers may seek to enter the market with bioequivalent products, potentially leading to significant price erosion.
• Reimbursement Pressures: Healthcare systems and private insurers may implement stricter reimbursement policies or prefer lower-cost alternatives, impacting profit margins.
• Competitor Innovation: The development of novel bowel preparation agents with even greater efficacy, improved safety profiles, or more convenient administration could challenge PLENVU's market position.
• Adverse Event Reporting: Any unexpected or serious adverse events associated with PLENVU, even if rare, could lead to regulatory scrutiny, label changes, or decreased physician confidence.
• Physician Prescribing Habits: Inertia in physician prescribing habits can slow adoption, as many physicians may be accustomed to prescribing older, less optimal agents.

Financial Considerations and Valuation

Valuation of PLENVU as an asset or product line requires a comprehensive financial model incorporating market size, projected market share, pricing strategies, cost of goods sold, R&D expenditures, sales and marketing costs, and patent cliff analysis.

Key Financial Metrics for Analysis

• Projected Revenue Growth: Based on market penetration rates, patient volumes, and pricing assumptions.
• Gross Margins: Reflecting manufacturing efficiency and competitive pricing.
• Operating Expenses: Including S&M, G&A, and ongoing R&D.
• Discounted Cash Flow (DCF): Estimating future cash flows and discounting them back to the present value, incorporating terminal growth rates and discount rates.
• Peer Group Multiples: Comparing PLENVU's valuation metrics (e.g., EV/Revenue, EV/EBITDA) to those of similar pharmaceutical products or companies.

The current market valuation of PLENVU, whether as a standalone product, part of a broader portfolio, or through licensing agreements, is contingent on its stage of market penetration, the strength of its IP, and anticipated revenue streams prior to patent expiration. Projections should account for the typical decline in revenue post-patent expiry due to generic entry.

Key Takeaways

PLENVU demonstrates significant clinical advantages in bowel preparation, offering improved efficacy and patient experience over traditional PEG formulations. Its robust intellectual property portfolio provides a period of market exclusivity, which, combined with favorable market trends like increased colonoscopy screening and a focus on procedural quality, positions it for continued growth. Investors and R&D strategists must weigh these strengths against the inherent risks of generic competition, evolving reimbursement landscapes, and competitor innovation. A thorough financial analysis, accounting for patent expiry timelines, is crucial for informed decision-making.

Frequently Asked Questions

1. What is the typical duration of patent protection for a drug like PLENVU? For a new drug formulation, patent protection typically extends 20 years from the filing date. This can be further extended through mechanisms like Patent Term Extension (PTE) in the U.S. and Supplementary Protection Certificates (SPCs) in Europe, often compensating for regulatory review delays.

2. How does PLENVU's safety profile compare to other bowel preparation agents? PLENVU is formulated with electrolytes to mitigate risks of dehydration and electrolyte imbalance. Compared to older sodium phosphate preparations, its safety profile is considered superior, particularly for patients with renal or cardiac conditions. It aims for improved tolerability over standard PEG solutions due to its palatability.

3. What are the primary regulatory hurdles for PLENVU's market entry and expansion? Regulatory hurdles include obtaining marketing authorization from health authorities (e.g., FDA, EMA) based on demonstration of safety and efficacy through clinical trials. Post-approval, ongoing pharmacovigilance, potential label updates based on new safety data, and navigating differing country-specific regulatory requirements are critical for market expansion.

4. What is the projected timeline for generic entry into the PLENVU market? The timeline for generic entry is dependent on the specific expiration dates of all relevant patents covering PLENVU's composition, method of use, and manufacturing processes, as well as any successful patent challenges or extensions. Companies must analyze patent litigation landscapes and expiration schedules, typically looking at the latter half of the 2020s and into the 2030s for significant generic pressure.

5. What is the impact of improved bowel preparation quality on patient outcomes and healthcare costs? Improved bowel preparation, as achieved by PLENVU, leads to higher adenoma detection rates, reducing the risk of missed colorectal cancers. This also minimizes the need for repeat colonoscopies, lowering overall healthcare expenditure. Better patient tolerability can also reduce procedure cancellations and improve patient adherence to screening recommendations.

Citations

[1] Data sourced from clinical trial publications and regulatory submission summaries for PLENVU. Specific references available upon request through proprietary databases. [2] Patient preference study data, available in marketing authorization dossiers and presented at scientific congresses.